Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   
 

Abstract | Full HTML Article | PDF ecancer 12 843 / https://doi.org/10.3332/ecancer.2018.843

Research

The pattern of comorbidities in cancer patients in Lagos, South-Western Nigeria

Purpose: Comorbidities have been indicated to influence cancer care and outcome, with strong associations between the presence of comorbidities and patient survival. The objective of this study is to determine the magnitude and pattern of comorbidities in Nigerian cancer populations, and demonstrate the use of comorbidity indices in predicting mortality/survival rates of cancer patients.

Methods: Using a retrospective study design, data were extracted from hospital reports of patients presenting for oncology care between January 2015 and December 2016 at two tertiary health facilities in Lagos, Nigeria. Patient comorbidities were ranked and weighted using the Charlson comorbidity index (CCI).

Results: The mean age for the 848 cancer patients identified was 53.9 ± 13.6 years, with 657 (77.5%) females and 191 (22.5%) males. Breast (50.1%), cervical (11.1%) and colorectal (6.3%) cancers occurred most frequently. Comorbidities were present in 228 (26.9%) patients, with the most common being hypertension (20.4%), diabetes (6.7%) and peptic ulcer disease (2.1%). Hypertension-augmented CCI scores were 0 (15.6%), 1–3 (62.1%), 4–6 (21.7%) and ≥7 (0.6%). The mean CCI scores of patients ≤50 years (0.8 ± 0.9) and ≥51 years (3.3 ± 1.2) were significantly different (p < 0.05). Patients with lower mean CCI scores were more likely to receive chemotherapy (2.2 ± 1.6 versus 2.5 ± 1.9; p < 0.05) and/or surgery (2.1 ± 1.5 versus 2.4 ± 1.7; p < 0.05).

Conclusion: Comorbidities occur significantly in Nigerian cancer patients and influence the prognosis, treatment outcome and survival rates of these patients. There is a need to routinely evaluate cancer patients for comorbidities with the aim of instituting appropriate multidisciplinary management measures where necessary.

Keywords: cancer, comorbidities, Charlson comorbidity index, Lagos, Nigeria

Loading Article Metrics ... Please wait

Related articles

Case Report: Chemotherapy and anti-HER2 therapy in metastatic breast cancer in pregnancy followed by surgical treatment

Abstract | Full Article | PDF | Spanish Published: 14 May 2019 / https://doi.org/10.3332/ecancer.2019.930

Clinical Study: Relevance of minor discrepancies at second pathology review in gynaecological cancer

Abstract | Full Article | PDF Published: 13 May 2019 / https://doi.org/10.3332/ecancer.2019.929

Research: Associated factors with the knowledge of nurses of a high complexity oncology centre in Brazil, on the management of cancer pain

Abstract | Full Article | PDF Published: 09 May 2019 / https://doi.org/10.3332/ecancer.2019.928

Short Communication: Prepectoral implant-based breast reconstruction: a joint consensus guide from UK, European and USA breast and plastic reconstructive surgeons

Abstract | Full Article | PDF Published: 07 May 2019 / https://doi.org/10.3332/ecancer.2019.927

Conference Report: Highlights from the 11th Breast-Gynecological and Immunooncology International Cancer Conference (BGICC), 17–18 January 2019, Egypt

Abstract | Full Article | PDF Published: 01 May 2019 / https://doi.org/10.3332/ecancer.2019.926



Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation